• Journal of Oral Medicine and Pain
• /
• 제36권3호
• /
• pp.199-205
• /
• 2011

근관치료 중 수동 또는 엔진구동파일을 사용하다 과도한 기구 조작을 하게 되면, 근관충전제, 드레싱제 그리고 근관세척제가 근관에서 나와 하악관으로 확산될 수 있다. 이 때 환자는 통증, 지각과민, 지각감퇴, 무감각, 이상감각 등을 호소하게 될 것이다. 이런 문제들은 근관충전제에 포함되어 있으면서 생체적합성이 떨어지는 물질들에 의한 비가역적인 손상을 피하기 위해 가능한 빨리 해결되어야 한다. 비록 근관치료와 관련하여 발생한 하치조신경의 손상을 치료하는 진료지침이 비교연구 되어 있는 것이 없으나, 이 합병증에 대한 통상의 치료는 통증과 염증을 조절하는 것이고, 가능하다면 수술적인 치료로 근원을 처치하는 것이다. 그러나, 비수술적인 치료로 통증을 완전히 개선하거나 감소시키고 또는 감각이상을 치료하는 것이 보고되어왔다. 가바펜틴(gabapentin) 또는 프리가발린(pregabalin) 같은 항간질제는 신경병증 통증의 치료에 이용되어 왔다. 이번 논문에서는 하악 우측 제 2대구치의 근관치료 후의 하치조신경의 손상과 이에 대해 프레드니솔론과 가바펜틴으로 비외과적 치료를 시행한 것과 임상적으로 신경감각검사와 신경전류인지역치검사(Neurometer)를 통해 경과관찰을 시행하였다.

• 전자공학회논문지SC
• /
• 제47권1호
• /
• pp.17-28
• /
• 2010

본 논문은 DSP를 이용한 새로운 형태의 TFT-LCD 자동 화질 최적화 시스템을 제안한다. 실제 산업 현장에서 이와 같은 화질 최적화 과정은 시행착오를 반복하는 형식으로 진행되어 많은 시간이 소요되고 있으며 LCD 개발 엔지니어들의 성향 및 숙련도에 따라 조정 결과에도 편차가 큰 문제점이 있다. 이러한 시스템은 평균 감마 오차, 감마 조정 시간 및 플리커 등을 줄이기 위해 모바일 LCD 구동 IC 내의 감마 조정 레지스터들과 전압 설정 레지스터들을 자동적으로 제어한다. 제안된 최적 화질 향상 시스템은 측정 대상이 되는 모듈 (MUT, LCD 모듈), 제어 프로그램, 휘도 측정용 멀티미디어 디스플레이 측정기 및 인터페이스용 제어 보드로 구성되어 있다. 개발된 시스템에는 참조 감마 곡선과의 6-점 프로그램 정합 기술을 이용한 새로운 알고리즘 및 자동 전압 설정 알고리즘이 내장되어 있다. 개발된 알고리즘과 프로그램은 범용 LCD 모듈에 적용가능하다. 또한 1.8, 2.0, 2.2 및 3.0 감마를 조정할 뿐만 아니라 플리커 수준을 자동으로 조절한다. 제어 보드는 DSP와 FPGA로 구성되어 있고, RGB 및 CPU와 같은 다양한 인터페이스들을 지원한다. 개발된 자동 감마 시스템은 기존의 시스템에 비해 현저히 짧은 감마 조정 시간 및 아주 작은 평균 감마 오차를 보였다. 또한 본 논문에서 제안하는 시스템은 최적화된 감마 곡선 설정을 이용한 개발 공정을 향상시키고, 고화질의 LCD를 제공하는데 아주 유용하다.

• 약학회지
• /
• 제47권5호
• /
• pp.339-344
• /
• 2003

Atenolol is a water soluble, ${\beta}_1$ selective adrenoceptor antagonist used in the treatment of angina and hypertension. It is primarily eliminated renally with minimal hepatic metabolism. The purpose of the present study was to evaluate the bioequivalence of Samchundang Atenolol (Samchundang Pharmaceutical Co., Korea.) to Tenolmin(Hyundai Pharmaceutical Ind. Co., Korea). The atenolol release from the two atenolol tablets in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty four normal male volunteers, 22.83$\pm$1.99 years in age and 65.82$\pm$7.15 kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one tablet containing 50 mg of atenolol was orally administered, blood was taken at predetermined time intervals and the concentrations of atenolol in serum were determined using HPLC method with fluorescence detector. The dissolution profiles of two atenolol tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_{t}$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_{t}$ and $C_{max}$ and untransformed $T_{max}$. The results showed that the differences in $AUC_{t}$, $C_{max}$ and $T_{max}$ between two tablets based on the Tenolmin were 3.74％, 4.38％ and 17.77％, respectively. There were no sequence effects between two tablets in these parameters. The 90％ confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(0.98)∼log(1.l1) and log(0.95)∼log(1.l5) for $AUC_{t}$ and $C_{max}$ respectively), indicating that Samchundang Atenolol tablet is bioequivalent to Tenolmin tablet.

• 재활복지공학회논문지
• /
• 제10권3호
• /
• pp.237-242
• /
• 2016

slip-ring 기술을 가진 spiral CT의 주요 장점으로는 X-ray 튜브의 연속적인 회전에 의해 환자에 대한 정보의 손실 없이 데이터를 연속적으로 획득할 수 있다는 것이다. 또한, X-선량의 인체 흡수의 감소를 위해서, 고시그널 저노이즈 및 빠른 데이터 획득 시간을 갖는 시스템이 요구되어 진다. 본 연구에서, CT 적용을 위해 다채널 포토센서 및 데이터 획득 시스템이 개발되어 졌다. 포토센서의 모듈은 16채널 CdWO4 크리스탈 및 실리콘 베이스의 포토다이오드가 사용되었다. 또한, 포토센서로 부터의 입력 신호에 대한 전기적인 증폭을 위해, 트랜스 임피던스 스위치 인테그레이터가 사용되었다. 스위치 인테그레이터는 CT 적용에 대해 적합한 시그널 밴드와 노이즈 퍼포먼스를 갖고 있다. 데이터 획득과 20 bit ADC 의 컨트롤은 FPGA를 이용하였고, 코딩은 VHDL을 사용하였다. CdWO4 기반의 실리콘 포토센서와 고SNR 및 좁은 시그널 밴드를 가진 증폭단 및 FPGA기반의 디지털 하드웨어는 CT적용 이외에 하드웨어 변경 없이 다른 분야에서도 이용 가능하다.

• 멤브레인
• /
• 제26권5호
• /
• pp.391-400
• /
• 2016

본 연구에서는 폴리술폰층 표면에 계면 중합 반응을 시켜 정삼투 복합 박막을 얻는 방법에 있어서, 지지층인 폴리술폰층과 활성층인 폴리아미드층 사이에 테트라에톡시실란 단량체의 졸-젤 반응을 통하여 고분자를 합성함으로써 친수성 경계층을 형성시키는 방법에 관한 제조법을 제시하였다. 폴리술폰층은 막 저항을 최소화하기 위하여 아주 얇은 부직포를 사용하였다. 테트라에톡시실란의 졸-젤 반응으로 형성된 고분자 경계층이 폴리술폰층과 폴리아미드층 사이에 형성된 정삼투 분리막은 친수화도, 유량 향상 등 정삼투 분리막 투과 특성에 있어 향상된 결과를 보여 주었다. 폴리아미드 계면 중합과 테트라에톡시실란 졸-젤 중합의 순서를 변화시킴으로써 표면 구조 특성 및 정삼투 투과 특성이 크게 달라짐을 볼 수 있었다. 정삼투막의 투과 특성은 실험실 용량의 정삼투 평가 장치를 통하여, 정삼투 분리막 내 폴리실록산의 분포와 구조는 FE-SEM과 EDAX를 이용하여 조사하였다. PS_PA_TEOS막의 경우 유량에 있어 79.2 LMH로 현격한 증가가 있었으나 염의 역확산 속도 역시 7.10 GMH로 증가하였다. 반면 PS_TEOS_PA막의 경우 PS_PA막에 비해 염의 역확산 속도는 1.60 GMH로 유지되면서 유량이 54.1 LMH로 증가하는 현상을 확인할 수 있었다.

• 대한약침학회지
• /
• 제3권1호
• /
• pp.35-51
• /
• 2000

The purpose of this study is to prove the analgesic effects of apitoxin and its mechanism via jaw-opening reflex(JOR) and measuring expression of mRNA in Phospholipase and Tryptophan hydroxylase(TPH) using RT-PCR. The experiments were carried out on Sprague-Dawley rats(300-400g) and mastocytoma(P-185 HTR) for JOR and RT-PCR, respectively. Rats anesthetized with thiopental sodium (80mg/kg) were used in the Tooth Pulp stimulation induced JOR. The amplitude of a digastric electromyogram (dEMG) was recorded during the stimulation at an intensity of 1.5 times the threshold for JOR. Apitoxin used in this experiment was diluted with normal saline by 1:1000. Apitoxin was injected intravenously into the test group while normal saline to the control group. However, it was injected directly into the cell of mastocytoma. We referred to base sequence registered in Genbank in designing primers for RT-PCR. The results were as follows; (1)Compared with control group, analgesic effect started to show right after Sprague-Dawely rats were treated with apitoxin($71.50{\pm}8.08$) and lasted for 50 minutes. (2)As a result of the experiment of RT-PCR, we witnessed significant changes in the degree of expression of phospholipase or rate-limiting enzyme of biosynthesis of prostaglandins with $10{\mu}g/ml$ apitoxin.($31.74{\pm}18.98%$, P<0.05) (3)As a result of the experiment of RT-PCR, we witnessed significant changes in the degree of expression of TPH or rate-limiting enzyme in biosynthesis of serotonin with $10{\mu}g/ml$ apitoxin.($131.37{\pm}16.87%$, P<0.05). These results suggest that $10{\mu}g/ml$ apitoxin have the most analgesic effects. This study showed that apitoxin has analgesic effects and held good for 50 minutes. The injection of apitoxin has brought out changes in the degree of expression of phospholipase and TPH. These results strongly suggest that analgesic mechanism by apitoxin is closely related to prostaglandins and serotonin.

• Journal of Pharmaceutical Investigation
• /
• 제32권1호
• /
• pp.47-54
• /
• 2002

Cimetropium bromide, a quaternary ammonium compound which is chemically related to scopolamine, exhibits its antispasmodic activity by competing with acetylcholine for the muscarinic receptors of the smooth muscle of gastrointestinal tract. The drug has been used for the treatment of various disorders involving spasms of the musculature of the gastrointestinal, biliary and genitourinary tracts. The purpose of the present study was to evaluate the bioequivalence of two cimetropium bromide tablets, $Algiron^{TM}$ (Boehringer Ingelheim Korea Ltd.) and $Alpit^{TM}$ (Hana Pharmaceutical Co., Ltd.), according to the prior and revised guidelines of Korea Food and Drug Administration (KFDA). The cimetropium bromide release from the two cimetropium bromide tablets in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty normal male volunteers, $25.25{\pm}2.10$ years in age and $65.76{\pm}6.39$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After three tablets containing 50 mg of cimetropium bromide per tablet were orally administered, blood was taken at predetermined time intervals and the concentrations of cimetropium bromide in serum were determined using HPLC method with UV detector. The dissolution profiles of two cimetropium bromide tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using non-transformed and logarithmically transformed $AUC_t\;and\;C_{max}$. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between two tablets based on the $Algiron^{TM}$ were 2.19%, -5.97% and 3.49%, respectively. Minimum detectable differences $({\Delta})\;at \;{\alpha}=0.05\;and\;1-{\beta}=0.8$ were less than 20% (e.g., 13.71 %, 19.05% and 15.11% for $AUC_t,\;C_{max}\;and\;T_{max}$, respectively). The powers $(1-{\beta})\;at\;{\alpha}=0.05,\;{\Delta}=0.2\;for\;AUC_t$, $C_{max}\;and\;T_{max}$ were 97.79%, 83.22% and 95.60%, respectively. The 90% confidence intervals were within ${\pm}20%$ (e.g., $-5.84{\sim}10.21,\;-17.11{\sim}5.18\;and\;-5.35{\sim}12.33\;for\;AUC_t,\;C_{max}\;and\;T_{max}$, respectively). There were no sequence effect between two tablets in logarithmically transformed $AUC_t\;and\;C_{max}$. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., $0.94{\sim}1.10\;and\;0.85{\sim}1.05\;for\;AUC_t\;and\;C_{max}$, respectively). Two parameters met the criteria of prior and revised KFDA guideline for bioequivalence, indicating that $Alpit^{TM}$ tablet is bioequivalent to $Algiron^{TM}$ tablet.

• Journal of Pharmaceutical Investigation
• /
• 제34권2호
• /
• pp.139-145
• /
• 2004

The purpose of the present study was to evaluate the bioequivalence of two risperidone tablets, Risperdal (Janssen Korea Co., Ltd.) and Rispen (Myung In Pharm. Co., Ltd), according to the guidelines of Korea Food and Drug Administration (KFDA). The risperidone release from the two risperidone formulations in vitro was tested using KP VIII Apparatus II method with various of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty four healthy male subjects, $23.33\;{\pm}2.10$ years in age and $69.24{\pm}8.05\;kg$ kg in body weight, were divided into two groups and a randomized $2\;{\times}\;2$ cross over study was employed. After one tablet containing 2 mg as risperidone was orally administered, blood was taken at predetermined time intervals and the concentrations of risperidone in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t$,$C_{max},\;and\;T_{max}$ were calculated and ANOVA test was utilized for the analysis of the parameters using logarithmically transformed $AUC_t$,$C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the Risperdal were 0.20, -1.29 and -11-09% for $AUC_t$,$C_{max},\;and\;T_{max}$, respectively There were no sequence effects two formulations in parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g.,$log(0.90){\sim}log(1.30)$ and $log(0.84){\sim}log(1.09)$ for$AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA guideline for the bioequivalence were satisfied, indicating Rispen tablet and Risperdal tablet were bioequivalent.

• Journal of Pharmaceutical Investigation
• /
• 제34권2호
• /
• pp.147-153
• /
• 2004

The purpose of the present study was to evaluate the bioequivalence of two glimepiride tablets, $Amaryl^{\circledR}$ (Handok/Aventis Pharm. Co., Ltd.) and Glimed (Kuhn II Pharm. Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The glimepiride release from the two glimepiride formulations in vitro was tested using KP VIII Apparatus II method with a variety of dissolution media (pH 1.2, 4.0, 6.8 buffer solution, water and blend of PSB 80 into each dissolution medium). Twenty six healthy male subjects, $22.65{\pm}2.19$ years in age and $66.55{\pm}8.85$ kg in body weight, were divided into two groups and a randomized $2\;{\times}\;2$ cross-over study was employed. After one tablet containing 2 mg as glimepiride was orally administered, blood was taken at predetermined time intervals and the concentrations of glimepiride in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the Amaryl were -3.70, -8.28 and 0.61% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., $log(0.84){\sim}log(1.04)$ for $log(0.82){\sim}log(1.03)$ for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA guideline for the bioequivalence were satisfied, indicating Glimed tablet and Amaryl tablet were bioequivalent.

• Journal of Microbiology and Biotechnology
• /
• 제26권6호
• /
• pp.1115-1123
• /
• 2016

_L-Asparaginase (E.C. 3.5.1.1) is an enzyme involved in asparagine hydrolysis and has the potential to effect leukemic cells and various other cancer cells. We identified the _L-asparaginase gene (_L-ASPG86) in the genus Mesoflavibacter, which consists of a 1,035 bp open reading frame encoding 344 amino acids. Following phylogenetic analysis, the deduced amino acid sequence of _L-ASPG86 (_L-ASPG86) was grouped as a type I asparaginase with respective homologs in Escherichia coli and Yersinia pseudotuberculosis. The _L-ASPG86 gene was cloned into the pET-16b vector to express the respective protein in E. coli BL21 (DE3) cells. Recombinant _L-asparaginase (r-_L-ASPG86) showed optimum conditions at 37-40℃, pH 9. Moreover, r-_L-ASPG86 did not exhibit glutaminase activity. In the metal ions test, its enzymatic activity was highly improved upon addition of 5 mM manganese (3.97-fold) and magnesium (3.35-fold) compared with the untreated control. The specific activity of r-_L-ASPG86 was 687.1 units/mg under optimum conditions (37℃, pH 9, and 5 mM MnSO₄).